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httpcense.Abstract Chronic obstructive pulmonary disease (COPD) is no longer considered to affect only
the lungs and airways but also the rest of the body. The systemic manifestations of COPD include
a number of endocrine disorders, such as those involving the pituitary, the thyroid, the gonads, the
adrenals and the pancreas.
Aim of the work: The aim of this work was to assess thyroid gland functions and hypogonadism
among male patients with COPD and its relation to diseases severity.
Patients and methods: The study included 60 male patients diagnosed as COPD were selected
and classiﬁed according to the Egyptian society for chest diseases and tuberculosis (ESCT) into
three groups (mild, moderate and sever COPD) where cases and their age matched controls were
evaluated as regard thyroid, gonadotrophins and androgen levels (TSH, FT3, FT4, FSH, LH,
DHEAS-S, testosterone total and free were measured).
Results: When we made comparison between patients with different grades of COPD as regard
thyroid, gonadotrophins and androgen levels we found statistical difference betweenmild versusmod-
erate and mild versus severe COPD as regard FT3 and mild versus moderate and severe COPD as
regard DAHEAS-S and testosterone. And, the study showed that’s there were statistical difference
as regard free testosterone among patients with COPD, but there was high statistical signiﬁcant dif-
ference as regard DHEAS-S and testosterone.1088315/222706175.
(A.M. Abdel Dayem).
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Patients with chronic obstructive pulmonary disease (COPD)
have a chronic illness. They are commonly hypoxaemic, hyper-
capnic or both have increased levels of systemic inﬂammatory
markers, and receive glucocorticoids. Each of these factors can
affect endocrine function [1].
Several risk factors thatmay decrease testosterone in patients
with COPD have been reported. These include ageing, chronic
disease, hypoxaemia, hypercapnia, smoking, administration of
glucocorticoids, systemic inﬂammation and obesity [2].
Abnormalities in thyroid hormone regulation are encoun-
tered frequently in nonthyroidal diseases; these include normal
or decreased total and free thyroxin (TT4 and FT4 respec-
tively), decreased total (TT3) and free (FT3) triiodothyronine
along with usually normal thyroid-stimulating hormone
(TSH) levels [3]. These changes have been observed primarily
in critical illness, such as starvation, sepsis, surgery, or myocar-
dial infarction, but also in diverse chronic, systemic conditions,
i.e., in chronic heart failure, chronic liver or hematological dis-
eases, cancer, diabetes, and in connective tissue disorders [4].
Aim of the work
The aim of this work was to assess thyroid gland functions and
hypogonadism among male patients with COPD and its rela-
tion to diseases severity.
Patients and methods
The study included 60 male patients diagnosed as COPD
according to Global Initiative for Chronic Obstructive Lung
Disease Criteria (GOLD) and the Egyptian Society for Chest
Diseases and Tuberculosis (ESCT). All patients were selected
from out patient’s clinics and in-patients department of the
chest department, Ain Shams University hospital (ASUH). A
control group of 60 healthy age matched males was included.
Exclusion criteria were: history of primary infertility, pres-
ence of other chronic diseases as: diabetesmellitus, hypertension
or cardiovascular disease, intake of iodine containing drugs.
All patients and control groups were subjected to the
followings:
1. Full history taking to diagnose COPD and exclude any
other chest diseases.
2. Clinical examination both general and local chest exam-
ination to diagnose COPD and exclude any other chest
diseases.
3. Answering a questionnaire about symptoms of late
onset hypogonadism (LOH) according to the European
male aging Study (EMAS) in 2010. The questionnaire
asked about 9 symptoms which were demonstrated to
have a signiﬁcant correlation with either total or free
testosterone. The questionnaire included assessment ofthree items: sexual, physical and psychological symp-
toms of LOH (Sexual: full morning erection, erection
sufﬁcient for intercourse, occurrence of sexual thoughts.
Physical: vigorous activity, capable of walking >1 km,
ability to bend and kneel. Psychological: feeling of sad-
ness or downheartedness, loss of energy, fatigue).
4. General examination: which was done in dermatology
and andrology department ASUH for signs of hypogo-
nadism as sparce axillary, pubic, facial and body hair,
muscle wasting, gynecomastia and fat distribution.
5. Chest X-ray poster anterior view to exclude any other
chest diseases.
6. Pulmonary function tests (PFT): it was done by Flo-
mate Spirometry 2500, in pulmonary function unit in
the chest department, Ain Shams University Hospital.
The pulmonary function results were expressed as per-
centages of predicted normal values. It selects, prints,
and summarizes the best test results, in addition to cal-
culating the measured and predicted values forced vital
capacity (FVC% of the predicted), forced expiratory
volume in the ﬁrst second (FEV1% of the predicted)
and ratio of FEV1 to FVC (FEV1/FVC%) forced expi-
ratory ﬂow (FEF 25–75%).The COPD patients were
selected and classiﬁed according to the Egyptian society
for chest diseases and tuberculosis (ESCT) into:
Group I. Mild COPD FEV1/FVC< 70% and
FEV1 > 80%(20 cases).
Group II. Moderate COPD FEV1/FVC< 70% and
FEV1 < 80% and >50% (20 cases).
Group III. Sever COPD FEV1/FVC< 70% and
FEV1 < 50% (20 cases).
7. Blood samples: 5 ml were taken from patients and con-
trolled subjects and then we centrifuging and stored at
20 until used for assays.
8. Biochemistry determinations: in the laboratory unit of
the chest department ASUH.
1. Serum levels of free triiodothyronine (FT3), free thyrox-
ine (FT4) and thyroid-stimulating hormone (TSH) were
determined.
2. Measurement of morning serum level of total and free
testosterone using immunoassay measurements and con-
sidering the cut off point for total testosterone is 8–
11 nmol/l and the cut off point for free testosterone is
<220 pmol/l.
3. Measurement of serum level of lutenising hormone
(LH), and serum dehydroepiandrosterone sulphate
(DHEAS).
Statistical analysis
The collected data was revised, coded, tabulated and intro-
duced to a PC using Statistical package for Social Science
Table 2 Comparison between group I (mild COPD) cases and
their age matched controls as regard thyroid, gonadotrophin
and androgen level.
Group P Sig
Cases Controls
Mean ±SD Mean ±SD
TSH 0.89 0.55 1.15 0.59 0.163 NS
FT3 2.95 0.87 2.82 0.86 0.646 NS
FT4 1.67 0.36 1.27 0.24 0.0001 HS
FSH 4.30 1.37 6.55 0.10 0.0001 HS
LH 4.54 1.14 6.38 0.04 0.0001 HS
DHEAS-S 240.61 36.02 327.30 4.81 0.0001 HS
Testosterone 4.14 0.66 4.70 0.07 0.001 HS
Free testosterone 13.47 4.62 19.80 0.55 0.0001 HS
*Student t test.
Table 3 Comparison between group II (moderate COPD)
cases and their age matched controls as regard age and PFT.
Cases Controls P Sig
Mean ±SD Mean ±SD
Age 65.15 9.70 64.30 64.30 0.850 NS
FVC% 90.20 11.21 94.00 6.91 0.205 NS
FEV1% 61.95 6.95 85.00 5.95 0.0001 HS
FEV1/FVC 66.04 3.31 94.43 5.34 0.0001 HS
*Student t test.
Table 4 Comparison between group II (moderate COPD)
cases and their age matched controls as regard thyroid,
gonadotrophin and androgen level.
Cases Controls P Sig
Mean ±SD Mean ±SD
TSH 0.99 0.77 1.87 0.42 0.0001 HS
FT3 1.97 0.78 2.91 0.61 0.0001 HS
FT4 1.36 0.44 1.29 0.21 0.544 NS
FSH 3.54 1.37 6.67 0.03 0.0001 HS
LH 4.13 1.14 6.43 0.03 0.0001 HS
DHEAS-S 124.62 14.23 332.57 3.82 0.0001 HS
Testosterone 3.84 0.58 4.80 0.02 0.0001 HS
Free testosterone 12.34 4.62 20.45 0.10 0.0001 HS
*Student t test.
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Quantitative variables are expressed as mean and SD. Qualita-
tive variables are expressed as frequencies and percents. Stu-
dent t test was used to compare a continuous variable
between two study groups. ANOVA test was used to compare
a continuous variable between more than two study groups.
Bonferroni post hoc test was used for pair wise comparison.
Correlation analysis using Pearson’s method was used to assess
the strength of association between two quantitative variables.
A signiﬁcance level of P< 0.005 was used in all tests.
Ethical aspects
The study was explained to the patients giving them a clear
idea about the investigations done to them and that they have
the right to withdraw from the study at any time.
Results
The study included 60 male patients diagnosed as COPD
according to Global Initiative for Chronic Obstructive Lung
Disease Criteria (GOLD) and the Egyptian society for chest
diseases and tuberculosis (ESCT). Each group was studied in
comparison to their matched control group.
In our study we found in group I (mild cases of COPD with
their matched control group), as regarding age was 53.9
(±13 SD) years in mild COPD patients and 52.6 (±10.2 SD)
in the control, FVC% was 88.70 (4.47 ± SD) in mild COPD
patients and 122.55 (4.11 ± SD) in the control, FEV1%
81.80 (4.66 ± SD) and 86.40 (8.13 ± SD) in the control,
FEV1/FVC 66.82 (4.14 ± SD) in mild COPD patients and
97.49 (9.19 ± SD) in the control. We found no statistical sig-
niﬁcant difference as regard age but high statistical signiﬁcant
difference as regard FVC, FEV1 and FEV1/FVC (P va-
lue < 0.001) (Table 1).
In our study we found in group I (mild cases of COPD with
their matched control group), as regarding TSH and FT3 there
was no statistical difference between mild cases of COPD with
their matched control group (P value was 0.163 and 0.646), but
there were high statistical signiﬁcant difference in FT4, FSH,
LH, DAHEAS and free and total testosterone. (P< 0.001)
(Table 2).
In our study we found in group II (moderate cases of
COPD with their matched control group), as regarding age
was 65.15 (±9.70 SD) years in moderate COPD patients and
64.30 (±64.30 SD) in the control, FVC% was 90.20
(11.21 ± SD) in moderate COPD patients and 94.00Table 1 Comparison between group I (mild COPD) cases and
their age matched controls as regard age and PFT.
Group P Sig
Cases Controls
Mean ±SD Mean ±SD
Age 53.9 13.0 52.6 10.2 0.727 NS
FVC% 88.70 4.47 122.55 4.11 0.0001 HS
FEV1% 81.80 4.66 86.40 8.13 0.034 S
FEV1/FVC 66.82 4.14 97.49 9.19 0.0001 HS
*Student t test.(6.91 ± SD) in the control, FEV1% 61.95 (6.95 ± SD) and
85.00 (5.95 ± SD) in the control, FEV1/FVC 66.04
(3.31 ± SD) in moderate COPD patients and 94.43
(5.34 ± SD) in the control (Table 3). We found no statistical
signiﬁcant difference as regard age and FVC but high statisti-
cal signiﬁcant difference as regard FEV1 and FEV1/FVC (P
value < 0.001) (Table 3).
In our study we found in group II (moderate cases of
COPD with their matched control group), as regarding FT4
there was no statistical difference between moderate cases of
COPD with their matched control group (P value was
Table 5 Comparison between group III (severe COPD) cases
and their age matched controls as regard age and PFT.
Cases Controls P Sig
Mean ±SD Mean ±SD
Age 70.50 8.02 69.10 10.61 0.640 NS
FVC% 67.60 7.55 85.80 6.39 0.205 NS
FEV1% 38.95 5.13 80.60 2.95 0.0001 HS
FEV1/FVC 57.91 6.79 94.36 6.99 0.0001 HS
*Student t test.
Table 6 Comparison between group III (severe COPD) cases
and their age matched controls as regard thyroid, gonadotro-
phin and androgen level.
Cases Controls P Sig
Mean ±SD Mean ±SD
TSH 0.76 0.57 1.85 0.42 0.0001 HS
FT3 1.98 0.48 2.84 0.56 0.0001 HS
FT4 1.50 0.39 1.25 0.25 0.019 S
FSH 4.15 2.25 6.68 0.06 0.0001 HS
LH 4.96 2.16 6.45 0.03 0.006 HS
DHEAS-S 24.13 9.23 332.52 3.80 0.0001 HS
Testosterone 2.86 .73 4.82 0.02 0.0001 HS
Free testosterone 10.10 4.64 20.47 0.10 0.0001 HS
*Student t test.
Table 7 Correlations between COPD grade and thyroid
hormonal levels.
TSH FT3 FT4
Grade R .081 .469 .164
P 0.538 0.0001 0.210
Sig NS HS NS
Grade
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Figure 1 Correlations between COPD grade and thyroid
hormonal levels.
Table 8 Correlations between COPD grade and gonadotro-
phin hormonal levels.
FSH LH
Grade R .036 0.111
P 0.783 0.397
Sig NS NS
Table 9 Correlations between COPD grade and androgen
hormonal levels.
DHEAS-S Testosterone Free testosterone
Grade R .969 .620 .292
P 0.0001 0.0001 0.024
Sig HS HS S
100 A.M. Abdel Dayem et al.0.544), but there were high statistical signiﬁcant difference in
TSH, FT3, FSH, LH, DAHEAS and free and total testoster-
one. (P< 0.001) (Table 4).
In our study we found in group III (sever cases of COPD
with their matched control group), as regarding age was
70.50 (±8.02 SD) years in sever COPD patients and 69.10
(±10.61) in the control, FVC% was 67.60 (7.55 ± SD) in se-
ver COPD patients and 85.80 (6.39 ± SD) in the control,
FEV1% 38.95 (5.13 ± SD) and 80.60 (2.95 ± SD) in the con-
trol, FEV1/FVC 57.91 (6.79 ± SD) in sever COPD patients
and 94.36 (6.99 ± SD) in the control. We found no statistical
signiﬁcant difference as regard age and FVC but high statisti-
cal signiﬁcant difference as regard FEV1 and FEV1/FVC (P
value < 0.001) (Table 5).
In our study we found in group III (sever cases of COPD
with their matched control group), as regarding FT4 there
was statistical difference between sever cases of COPD with
their matched control group (P value was 0.019), but there
were high statistical signiﬁcant difference in TSH, FT3, FSH,
LH, DAHEAS and free and total testosterone. (P< 0.001)
(Table 6).Table 7 shows correlations between the three groups of the
COPD and the thyroid hormonal level, there were no statisti-
cal difference as regard TSH and FT4 but there was high sta-
tistical signiﬁcant difference as regard FT3 in relation to
diseases severity of COPD (Fig. 1).
Table 8 shows correlations between the three groups of the
COPD and the gonadotrophins hormonal level; there were no
statistical difference as regard FSH and LH in relation to dis-
eases severity of COPD.
Table 9 shows correlations between the three groups of the
COPD and the androgen hormonal level, there were statistical
difference as regard free testosterone but there was high statis-
tical signiﬁcant difference as regard DHEAS-S and testoster-
one in relation to diseases severity of COPD (Figs. 2–4).
When we made comparison between patients with different
grades of COPD as regard thyroid, gonadotrophins and
androgen levels we found statistical difference between mild
versus moderate and mild versus severe COPD as regard
FT3 and mild versus moderate and severe COPD as regard
DAHEAS-S and testosteroneTable 10.
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Figure 2 Correlations between COPD grade and DHEAS-S.
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Figure 3 Correlations between COPD grade and free
testosterone.
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Figure 4 Correlations between COPD grade and testosterone.
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Chronic obstructive pulmonary disease (COPD) is no longer
considered to affect only the lungs and airways but also the
rest of the body. The systemic manifestations of COPD include
a number of endocrine disorders, such as those involving the
pituitary, the thyroid, the gonads, the adrenals and the pan-
creas [5].
Abnormalities in thyroid hormone regulation are encoun-
tered frequently in nonthyroidal diseases; these include normal
or decreased total and free thyroxin (TT4 and FT4 respec-
tively), decreased total (TT3) and free (FT3) triiodothyronine
along with usually normal thyroid-stimulating hormone
(TSH) levels (2). These changes have been observed primarily
in critical illness, such as starvation, sepsis, surgery, or myocar-
dial infarction, but also in diverse chronic, systemic conditions,
i.e., in chronic heart failure, chronic liver or hematological dis-
eases, cancer, diabetes, and in connective tissue disorders [4].In men and women, the gonadal axis is a complex network
of hormones that includes testosterone, an important anabolic
hormone. In men, the main production site of androgens is the
testicle [6]. An important contributor to this decline is a de-
crease in LH (hypogonadotrophic hypogonadism), the most
common presentation of late-onset hypogonadism in men with
COPD. Whether COPD is a ‘‘chronic illness’’ that can cause,
by itself, hypogonadism is controversial considering that
among ambulatory men with COPD severity of lung disease
does not predict the hormonal abnormality (7).
In our study when we made comparison between group I
(mild COPD) cases and their age matched controls as regard
age and PFT, we found no statistical signiﬁcant difference as
regard age between mild COPD and their control group but
high statistical signiﬁcant difference as regard FVC, FEV1
and FEV1/FVC (P value < 0.001) this were because of the
inclusion criteria. This was in agreement with [8,9] who found
insigniﬁcant difference in stages of pulmonary function with
age and sex.
Secretion is stimulated by luteinising hormone (LH), one of
the pituitary gonadotropins. Under physiological conditions,
about 44% of circulating testosterone is strongly bound to
the sex hormone binding globulin; 54% is weakly bound to
albumin and other lower afﬁnity, high-capacity binding sites,
about 2% of circulating testosterone is nonprotein bound,
i.e. free testosterone. Together, weakly bound testosterone
and free testosterone are referred to as ‘‘bioavailable testoster-
one’’ [20].
When we made comparison between group I (mild COPD)
cases and their age matched controls as regard thyroid, gonad-
otrophin and androgen level in group I (mild cases of COPD
with their matched control group), as regarding TSH and
FT3 there was no statistical difference between mild cases of
COPD with their matched control group (P value was 0.163
and 0.646), but there were high statistical signiﬁcant difference
in FT4, FSH, LH, DAHEAS and free and total testosterone
(P< 0.001).
We found comparison between group II (moderate COPD)
cases and their age matched controls as regard age and PFT no
statistical signiﬁcant difference as regard age and FVC but
Table 10 Comparison between patients with different grades of COPD as regard thyroid, gonadotrophins and androgen levels.
Grade P* Sig Post Hoc test**
Mild COPD Moderate COPD Severe COPD
Mean ±SD Mean ±SD Mean ±SD
TSH .89 .55 .99 .77 .76 .57 .547 NS –
FT3 2.95 .87 1.97 .78 1.98 .48 .001 HS Mild vs mod
mild vs severe
FT4 1.67 .36 1.36 .44 1.50 .39 .056 NS –
FSH 4.30 1.37 3.54 1.37 4.15 2.25 .347 NS –
LH 4.54 1.14 4.13 1.14 4.96 2.16 .246 NS –
DHEAS-S 240.61 36.02 124.62 14.23 24.13 9.23 .0001 HS Mild vs modmild vs severe
mod vs severe
Testosterone 4.14 .66 3.84 .58 2.86 .73 .0001 HS Mild vs severe
mod vs severe
Free testosterone 13.47 4.62 12.34 4.62 10.10 4.64 .072 NS –
* ANOVA.
** Bonferroni.
 HS.
102 A.M. Abdel Dayem et al.high statistical signiﬁcant difference as regard FEV1 and
FEV1/FVC (P value < 0.001) this were because of the inclu-
sion criteria. This was in agreement with [8,9] who found insig-
niﬁcant difference in stages of pulmonary function with age
and sex.
The concentration of serum testosterone and other andro-
gens, such as the adrenal steroid dehydroepiandrosterone
(DHEA), a testosterone precursor, decline in middle aged
and elderly men. When excessive, this decline may contribute
to various signs and symptoms, including decreased energy le-
vel, libido, bone density and muscle mass and, possibly, reduc-
tions in cognitive function and memory [12].
In our study we found in comparison between group II
(moderate COPD) cases and their age matched controls as re-
gard thyroid, gonadotrophin and androgen level, as regarding
FT4 there was no statistical difference between moderate cases
of COPD with their matched control group (P value was
0.544), but there were high statistical signiﬁcant difference in
TSH, FT3, FSH, LH, DAHEAS and free and total testoster-
one. (P< 0.001). This was in contrast with [13], who said,
whether COPD is a ‘‘chronic illness’’ that can cause, by itself,
hypogonadism is controversial considering that among ambu-
latory men with COPD severity of lung disease does not pre-
dict the hormonal abnormality. Also, the number of co
morbid conditions in hypogonadal and eugonadal men with
COPD is similar [13].
We found, group III (severe COPD) cases and their age
matched controls as regard age and PFT no statistical signiﬁ-
cant difference as regard age and FVC but high statistical sig-
niﬁcant difference as regard FEV1 and FEV1/FVC (P
value < 0.001) this were because of the inclusion criteria. This
was in agreement with [8,9] who found insigniﬁcant difference
in stages of pulmonary function with age and sex [10].
In our study we found in, comparison between group III
(severe COPD) cases and their age matched controls as regard
thyroid, gonadotrophin and androgen level in group III (sever
cases of COPD with their matched control group), as regard-
ing FT4 there was statistical difference between sever cases
of COPD with their matched control group (P value was
0.019), but there were high statistical signiﬁcant difference inTSH, FT3, FSH, LH, DAHEAS and free and total testoster-
one. (P< 0.001). This was in contrast with [11], whom found
the prevalence of hypogonadism seems to be unaffected by
severity of COPD when patients are in a stable clinical condi-
tion, acute exacerbations and, possibly, the need for prolonged
mechanical ventilation, can (further) decrease testosterone.
When we made comparison between patients with different
grades of COPD as regard thyroid, gonadotrophins and
androgen levels we found statistical difference between mild
versus moderate and mild versus severe COPD as regard
FT3 and mild versus moderate and severe COPD as regard
DAHEAS-S and testosterone. This in agreement with [14],
who said, compared with moderate COPD, patients with se-
vere COPD (FEV1, 50%) demonstrate reductions in total T3
and in the T3/T4 ratio (a marker of peripheral conversion of
the prohormone (T4) to the active cellular form of the thyroid
hormone (T3)). In addition, low FEV1 is associated with low
basal and stimulated levels of thyroid stimulating hormone
(TSH). Also [15] reported a prevalence of late-onset hypogo-
nadism in 51% of 78 men with COPD and 26% of 21 age-
matched controls. These results do not necessary mean that
late-onset hypogonadism is more prevalent in men with COPD
than in the general population. The prevalence of hypogonad-
ism in the small control group was much lower than the 34–
40% prevalence of hypogonadism for subjects in their 60s
and the near 70% prevalence for subjects in their 70s, reported
in large population studies. Levels of testosterone did not cor-
relate with severity of airway obstruction or with a PaO2
.55 mmHg or glucocorticoid therapies.
Also in a study of 36 men with COPD, 25 of whom were
hypogonadal, the prevalence of sexual difﬁculties was not
associated with the level of free testosterone. COPD and
late-onset hypogonadism can decrease quality of life [16].
The apparent greater impact on quality of life of erectile dys-
function (ED) and lack of sexual interest in community dwell-
ing men than in men with COPD raises the possibility that
elderly men with COPD have fewer expectations associated
with sexual activity than their community welling counter-
parts. Possible reasons for the fewer expectations include the
realization that respiratory symptoms are permanent [17] loss
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aspect of sex [18]. The possibility that men with COPD have
fewer expectations associated with sexual activity, however,
is difﬁcult to reconcile with the observation that 29 of the 38
patients who were unable to climax (77%) were bothered by
this limitation, a ﬁgure that is similar to that reported among
community-dwelling men (73%) [19,20].
Conclusion
After the assessment of thyroid gland functions and hypogo-
nadism among male patients with COPD, we found that,
hypogonadism increases with age and the degree of severity
of COPD. The value of testosterone treatment in older men
with COPD remains to be investigated.
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